Answer Summary

Members confirmed that two years of immunotherapy maintenance after initial chemotherapy is now standard treatment for advanced or recurrent... Read more

Members confirmed that two years of immunotherapy maintenance after initial chemotherapy is now standard treatment for advanced or recurrent endometrial and ovarian cancers, with several sharing they received Keytruda, Jemperli, or similar drugs following six rounds of combination chemotherapy. Many members described positive outcomes, including one member who became cancer-free after just one year of immunotherapy and another who completed the full two years with no evidence of disease, though some noted their treatment was stopped early due to side effects like joint pain or because the therapy was no longer effective at controlling cancer growth. A recurring theme was that doctors typically present three possible timelines: continuing for the full two years, stopping if it becomes ineffective, or discontinuing if side effects become intolerable, with members emphasizing the importance of monitoring progress through scans and being prepared to adjust the plan as needed.